COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
Vaccine
; 38(33): 5085-5088, 2020 07 14.
Article
in English
| MEDLINE | ID: covidwho-680832
ABSTRACT
While a human challenge study holds the prospect of accelerating the development of a vaccine for the coronavirus SARS-CoV-2, it may be opposed due to risks of harm to participants and researchers. Given the increasing number of human deaths and severe disruption to lives worldwide, we argue that a SARS-CoV-2 challenge study is ethically justifiable as its social value substantially outweighs the risks. Such a study should therefore be seriously considered as part of the global research response towards the COVID-19 pandemic. In this paper, we contribute to the debate by addressing the misperception that a challenge study for the coronavirus would lower scientific and ethical standards for vaccine research and development, and examine how it could be ethically conducted. We also set out information that needs to be disclosed to prospective participants to obtain their consent.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Viral Vaccines
/
Vaccination
/
Coronavirus Infections
/
Biomedical Research
/
Pandemics
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Vaccine
Year:
2020
Document Type:
Article
Affiliation country:
J.vaccine.2020.06.007
Similar
MEDLINE
...
LILACS
LIS